Allianz’s Blueprint Medicines BPMC Stock Holding History

Allianz’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-700	Closed	-$75.4K	–	389
2024 Q2	$75.4K	Hold	700	–	–	﹤0.01%	381
2024 Q1	$66.4K	Buy	+700	New	+$60K	﹤0.01%	389

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Allianz's BPMC Position: Q3 2024 in Review

Allianz sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 700 shares — an estimated $75.4K sold.

Allianz first reported a position in BPMC in Q1 2024 and held it in 2 quarters. The position peaked at $75.4K in Q2 2024. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

Allianz reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
Allianz sold 700 Blueprint Medicines shares in Q3 2024, an estimated $75.4K.
Allianz first reported a position in Blueprint Medicines in Q1 2024 and held it in 2 quarters.
Allianz's Blueprint Medicines position peaked at $75.4K in Q2 2024.
319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on Allianz's 13F filing for Q3 2024, filed 12 May 2025.